Looking for your Altrata login? Sign in here to access your account

Altrata Log in
Skip to content
Asia Pacific
Dollar On The Back Foot As Focus Turns To Fed Easing
Alibaba Plunges $20 Billion As Chip War Prompts Breakup Rethink
Published by: dailynews
Published on:

Chinese Biopharma Firm Wuxi XDC Climbs 31% On Debut In Hong Kong

Published by: dailynews
Published on:

A Chinese maker of drugs used in cancer treatments surged in Hong Kong after an initial public offering priced at the top of a marketed range, a rare case of strong demand for a listing in the financial hub this year.

Shares of WuXi XDC Cayman Inc. gained 31% at the open to HK$26.95. The biopharmaceutical company raised HK$3.68 billion ($471 million) from the share sale, with the stock priced at HK$20.60 apiece compared with a starting level of $19.90. It’s the first among 14 listings larger than $100 million in the city this year that was priced at the highest indicated value, Bloomberg-compiled data showed.

Read the full story here.